How Cannabis May Reduce Chemotherapy-Related Nausea

Managing CINV in Geriatric Oncology: The Role of Cannabinoid Pharmacokinetics

For the aging patient, chemotherapy-induced nausea and vomiting (CINV) represents a physiological challenge that tests a body already dealing with diminished internal resources. As patients age, natural endocannabinoid tone—the body’s innate signaling system—often declines, which may leave seniors with fewer defenses against the systemic stress of oncology treatments. Integrating phytocannabinoids may support the restoration of biological equilibrium that chemotherapy often disrupts.

The Decline of Endocannabinoid Tone

The aging body produces fewer endogenous ligands, specifically anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Because these molecules support homeostasis, their depletion may make the geriatric patient more susceptible to CINV. By introducing exogenous phytocannabinoids, it is possible to supplement the body's reserves, which may help stabilize the internal signaling pathways involved in nausea regulation.

Neutralizing the Vomiting Reflex

The brainstem’s Dorsal Vagal Complex (DVC) serves as a control center for the emetic reflex. In seniors, increased blood-brain barrier permeability can make central receptors more accessible. Delta-9-THC may act as an inhibitor here, binding to CB1 receptors to influence the release of glutamate and substance P—signals associated with the vomiting reflex. Using low-dose THC may assist in modulating these signals while minimizing the intensity of effects like sedation or confusion.

Targeting Inflammation at the Source

Cytotoxic drugs can irritate the gastrointestinal tract, causing a surge in serotonin from enterochromaffin cells. This inflammation is a primary driver of the vagal signals that trigger nausea.

• CB2 Activation: CBD and THC engage CB2 receptors located on gut-resident immune cells. This may suppress pro-inflammatory cytokines like TNF-alpha, which could help reduce gut inflammation before it signals the brain to trigger a purge.
• Motility Regulation: Low-dose cannabinoids may assist in stabilizing gastric motility, which can reduce the heavy sensation that often contributes to nausea.

Navigating Polypharmacy and the P450 Pathway

A critical safety consideration for geriatric patients is drug-drug interaction. The Cytochrome P450 (CYP450) enzyme system in the liver manages the metabolism of many common medications, including statins and anticoagulants like Warfarin. CBD is a known inhibitor of CYP3A4, which can cause these medications to build up in the blood.

To mitigate this, patients may benefit from delivery methods that bypass "first-pass" liver metabolism. Sublingual tinctures and transdermal patches often provide an alternative to edibles, as they allow cannabinoids to enter the bloodstream directly, which may reduce the metabolic burden on the liver.

Mitigating Risks: The Entourage Effect

Cognitive preservation is a priority for any senior patient. The risk of falls or disorientation can be managed by choosing "entourage" profiles that balance THC’s effects:

• Alpha-Pinene: Acts as an acetylcholinesterase inhibitor, which may support memory and focus, potentially counteracting THC-related cognitive fog.
• Linalool: Provides anxiolytic benefits that may address the psychological component of anticipatory nausea.
• Beta-Caryophyllene: Functions as a dietary cannabinoid that targets CB2 receptors for systemic inflammation without psychoactive interference.

Supporting Bone Health

Many geriatric oncology protocols—specifically those for prostate and breast cancer—involve therapies that accelerate bone density loss. Emerging data suggest that CB2 receptor activation modulates the balance between osteoblasts (bone-building cells) and osteoclasts (bone-resorbing cells). Integrating a CB2-dominant approach may offer a dual benefit: managing nausea while providing a layer of support against treatment-induced bone degradation.

Strategic Administration

The goal for the geriatric patient is consistency rather than intensity.

• Nano-emulsified liquids offer higher bioavailability, allowing for lower, more precise doses.
• Transdermal patches provide a steady 12-to-24-hour release, avoiding the peaks and valleys that contribute to dizziness.

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 323(7303):16-21. PubMed

2. Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344-64. PubMed

3. Parker LA, Rock EM, Limebeer CL. (2011). Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 163(7):1411-22. PubMed

4. Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. (2008). Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care. 17(5):431-43. PubMed